Compare · BMRA vs NNNN
BMRA vs NNNN
Side-by-side comparison of Biomerica Inc. (BMRA) and Anbio Biotechnology (NNNN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BMRA and NNNN operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NNNN is the larger of the two at $4.16B, about 614.5x BMRA ($6.8M).
- Over the past year, BMRA is down 42.3% and NNNN is up 319.5% - NNNN leads by 361.8 points.
- NNNN has been more active in the news (8 items in the past 4 weeks vs 5 for BMRA).
- Company
- Biomerica Inc.
- Anbio Biotechnology
- Price
- $2.18-0.91%
- $28.00+1.86%
- Market cap
- $6.8M
- $4.16B
- 1M return
- -0.91%
- +3.74%
- 1Y return
- -42.33%
- +319.48%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 5
- 8
- Recent ratings
- 0
- 0
Biomerica Inc.
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Latest BMRA
- Biomerica's inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026
- Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway
- Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs
- Biomerica Reports Third Quarter Fiscal 2026 Financial Results
- SEC Form 10-Q filed by Biomerica Inc.
- Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe
- Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain
- SEC Form S-8 filed by Biomerica Inc.
- Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy
- Vietnam Approves Biomerica's EZ Detect™ for Nationwide Distribution
Latest NNNN
- SEC Form 6-K filed by Anbio Biotechnology
- Amendment: SEC Form 20-F/A filed by Anbio Biotechnology
- SEC Form 3 filed by new insider Song Suki
- SEC Form 3 filed by new insider Hartzler Nancy
- SEC Form 3 filed by new insider Lau Michael
- SEC Form 3 filed by new insider Tian Chris
- SEC Form 3 filed by new insider Xu Cany
- SEC Form 20-F filed by Anbio Biotechnology
- Anbio Biotechnology to Participate in KeyBanc Capital Markets Healthcare Forum
- SEC Form 6-K filed by Anbio Biotechnology